Agilent are working to increase the utility of NGS in the diagnostics field and in personalized medicine. We recently spoke with Ronda Allen, Head of R&D at Agilent, to learn more about two of Agilent's newest products in this space, the Cancer All-in-one (AIO) panels, and the Magnis NGS Library Prep System.Read More
Technology Networks recently spoke with Rosengarten and Raymond Mercier, VP and GM, Molecular Biology, Thermo Fisher Scientific, to learn more about how the co-marketing agreement between Thermo Fisher Scientific and Genialis will help ease the burden of the "informatics bottleneck" for research scientists.Read More
Surgery, when used as a cancer treatment, is a procedure in which a surgeon identifies and removes the cancerous tissue from a patient’s body. We recently spoke with Christopher Barys, CEO at On Target Laboratories to learn more about the novel cancer imaging agents they are currently developing, designed to help surgeons identify and resect cancerous lesions.Read More
A recent collaboration between Onconova Therapeutics and Mission will utilize the Mission Bio TapestriⓇ Platform to conduct targeted single-cell DNA analysis for the study of Onconova's novel cancer therapy, Rigosertib. We spoke with Darrin Crisitello, CCO of Mission Bio, to learn more.
Recent developments in MS technology have enabled a fourth dimension of analysis: ion mobility separation. The term "4D proteomics" has been created to describe analysis that incorporates all four dimensions. We interviewed two researchers at the forefront of the proteomics field to learn more about how 4D proteomics approaches are enhancing their research.
10 things to note about viral vector manufacturing, regarding the complexities and challenges, and the technology that will help drive cell and gene therapy forward. Here we share insights from Pall and Molmed representatives, who are leaders in the fields of bioprocessing and cell and gene therapy.Read More
We recently spoke with Paul Wotton, Ph.D., CEO at Obsidian Therapeutics, to gain his insights on the genetically engineered cell-therapy research area, and to learn how Obsidian Therapeutics' cytoDRiVE platform can increases the specificity and safety of such therapies.Read More